American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 913 Thousand USD | -58.84% |
| 2021 | 2.21 Million USD | -46.52% |
| 2020 | 4.14 Million USD | 13.46% |
| 2019 | 3.65 Million USD | -5.6% |
| 2018 | 3.87 Million USD | -21.2% |
| 2017 | 4.91 Million USD | -12.39% |
| 2016 | 5.6 Million USD | -11.21% |
| 2015 | 6.31 Million USD | -13.29% |
| 2014 | 7.28 Million USD | -18.09% |
| 2013 | 8.89 Million USD | -4.81% |
| 2012 | 9.34 Million USD | 0.77% |
| 2011 | 9.27 Million USD | -11.03% |
| 2010 | 10.42 Million USD | 7.15% |
| 2009 | 9.72 Million USD | -23.16% |
| 2008 | 12.65 Million USD | -8.76% |
| 2007 | 13.87 Million USD | 0.25% |
| 2006 | 13.83 Million USD | 6.32% |
| 2005 | 13.01 Million USD | 6.32% |
| 2004 | 12.24 Million USD | -1.95% |
| 2003 | 12.48 Million USD | 21.06% |
| 2002 | 10.31 Million USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 7.65 Million USD | 8.74% |
| 1999 | 7.03 Million USD | 219.91% |
| 1998 | 2.2 Million USD | 260.14% |
| 1997 | 610.87 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | - USD | -100.0% |
| 2023 Q1 | 164 Thousand USD | -1.8% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | 185 Thousand USD | -47.29% |
| 2022 Q1 | 351 Thousand USD | -31.04% |
| 2022 FY | 913 Thousand USD | -58.84% |
| 2022 Q4 | 167 Thousand USD | -20.1% |
| 2022 Q3 | 209 Thousand USD | 12.97% |
| 2021 Q4 | 509 Thousand USD | -17.1% |
| 2021 FY | 2.21 Million USD | -46.52% |
| 2021 Q1 | 566 Thousand USD | -27.16% |
| 2021 Q2 | 529 Thousand USD | -6.54% |
| 2021 Q3 | 614 Thousand USD | 16.07% |
| 2020 FY | 4.14 Million USD | 13.46% |
| 2020 Q2 | 1.75 Million USD | 141.15% |
| 2020 Q3 | 883 Thousand USD | -49.77% |
| 2020 Q1 | 729 Thousand USD | -17.16% |
| 2020 Q4 | 777 Thousand USD | -12.0% |
| 2019 Q1 | 923 Thousand USD | 4.41% |
| 2019 Q2 | 958 Thousand USD | 3.79% |
| 2019 Q3 | 895 Thousand USD | -6.58% |
| 2019 Q4 | 880 Thousand USD | -1.68% |
| 2019 FY | 3.65 Million USD | -5.6% |
| 2018 FY | 3.87 Million USD | -21.2% |
| 2018 Q4 | 884 Thousand USD | 0.68% |
| 2018 Q3 | 878 Thousand USD | -17.87% |
| 2018 Q1 | 1.04 Million USD | 10.86% |
| 2018 Q2 | 1.06 Million USD | 2.69% |
| 2017 Q1 | 1.31 Million USD | 8.13% |
| 2017 Q3 | 1.35 Million USD | 3.68% |
| 2017 Q4 | 939 Thousand USD | -30.65% |
| 2017 FY | 4.91 Million USD | -12.39% |
| 2017 Q2 | 1.3 Million USD | -0.76% |
| 2016 Q4 | 1.21 Million USD | -14.11% |
| 2016 FY | 5.6 Million USD | -11.21% |
| 2016 Q1 | 1.47 Million USD | 0.89% |
| 2016 Q2 | 1.5 Million USD | 2.38% |
| 2016 Q3 | 1.41 Million USD | -5.85% |
| 2015 Q4 | 1.45 Million USD | -8.36% |
| 2015 Q2 | 1.76 Million USD | 17.71% |
| 2015 Q3 | 1.59 Million USD | -10.07% |
| 2015 FY | 6.31 Million USD | -13.29% |
| 2015 Q1 | 1.5 Million USD | -10.65% |
| 2014 FY | 7.28 Million USD | -18.09% |
| 2014 Q1 | 2.04 Million USD | -4.17% |
| 2014 Q2 | 1.81 Million USD | -11.36% |
| 2014 Q4 | 1.68 Million USD | -3.94% |
| 2014 Q3 | 1.75 Million USD | -3.37% |
| 2013 Q3 | 2.25 Million USD | -5.17% |
| 2013 Q4 | 2.13 Million USD | -5.54% |
| 2013 FY | 8.89 Million USD | -4.81% |
| 2013 Q2 | 2.38 Million USD | 12.0% |
| 2013 Q1 | 2.12 Million USD | -7.69% |
| 2012 Q4 | 2.3 Million USD | 0.83% |
| 2012 Q3 | 2.28 Million USD | -7.27% |
| 2012 Q2 | 2.46 Million USD | 7.23% |
| 2012 Q1 | 2.29 Million USD | -3.29% |
| 2012 FY | 9.34 Million USD | 0.77% |
| 2011 Q1 | 2.04 Million USD | -12.48% |
| 2011 FY | 9.27 Million USD | -11.03% |
| 2011 Q3 | 2.36 Million USD | -4.87% |
| 2011 Q4 | 2.37 Million USD | 0.38% |
| 2011 Q2 | 2.48 Million USD | 21.45% |
| 2010 Q2 | 3.12 Million USD | 28.85% |
| 2010 FY | 10.42 Million USD | 7.15% |
| 2010 Q4 | 2.33 Million USD | -7.55% |
| 2010 Q3 | 2.53 Million USD | -19.07% |
| 2010 Q1 | 2.42 Million USD | 12.16% |
| 2009 Q3 | 2.5 Million USD | -10.93% |
| 2009 FY | 9.72 Million USD | -23.16% |
| 2009 Q1 | 2.25 Million USD | -1.49% |
| 2009 Q2 | 2.8 Million USD | 24.52% |
| 2009 Q4 | 2.16 Million USD | -13.51% |
| 2008 Q1 | 3.29 Million USD | -1.49% |
| 2008 FY | 12.65 Million USD | -8.76% |
| 2008 Q2 | 3.46 Million USD | 5.03% |
| 2008 Q4 | 2.28 Million USD | -36.49% |
| 2008 Q3 | 3.6 Million USD | 4.01% |
| 2007 Q3 | 3.91 Million USD | 13.85% |
| 2007 Q4 | 3.34 Million USD | -14.39% |
| 2007 FY | 13.87 Million USD | 0.25% |
| 2007 Q1 | 3.17 Million USD | -0.19% |
| 2007 Q2 | 3.43 Million USD | 8.22% |
| 2006 FY | 13.83 Million USD | 6.32% |
| 2006 Q1 | 3.42 Million USD | 26.78% |
| 2006 Q2 | 3.67 Million USD | 7.22% |
| 2006 Q3 | 3.56 Million USD | -2.89% |
| 2006 Q4 | 3.18 Million USD | -10.75% |
| 2005 Q3 | 3.57 Million USD | -1.22% |
| 2005 Q4 | 2.7 Million USD | -24.37% |
| 2005 Q2 | 3.61 Million USD | 15.76% |
| 2005 Q1 | 3.12 Million USD | 14.7% |
| 2005 FY | 13.01 Million USD | 6.32% |
| 2004 Q1 | 3.07 Million USD | 14.41% |
| 2004 Q4 | 2.72 Million USD | -16.35% |
| 2004 Q2 | 3.19 Million USD | 3.91% |
| 2004 Q3 | 3.25 Million USD | 1.94% |
| 2004 FY | 12.24 Million USD | -1.95% |
| 2003 Q2 | 3.17 Million USD | 19.71% |
| 2003 Q1 | 2.64 Million USD | 10.01% |
| 2003 Q4 | 2.68 Million USD | -32.52% |
| 2003 Q3 | 3.97 Million USD | 25.48% |
| 2003 FY | 12.48 Million USD | 21.06% |
| 2002 FY | 10.31 Million USD | 0.0% |
| 2002 Q1 | 2.2 Million USD | 0.0% |
| 2002 Q2 | 2.66 Million USD | 20.61% |
| 2002 Q3 | 3.03 Million USD | 13.86% |
| 2002 Q4 | 2.4 Million USD | -20.58% |
| 2001 FY | - USD | -100.0% |
| 2001 Q3 | 1.62 Million USD | 5.1% |
| 2001 Q2 | 1.55 Million USD | -6.74% |
| 2001 Q1 | 1.66 Million USD | 0.97% |
| 2000 Q2 | 2.15 Million USD | 34.1% |
| 2000 FY | 7.65 Million USD | 8.74% |
| 2000 Q3 | 2.02 Million USD | -6.22% |
| 2000 Q1 | 1.6 Million USD | -10.57% |
| 2000 Q4 | 1.64 Million USD | -18.56% |
| 1999 Q2 | 2.12 Million USD | 12.18% |
| 1999 Q3 | 2.12 Million USD | -0.24% |
| 1999 FY | 7.03 Million USD | 219.91% |
| 1999 Q4 | 1.79 Million USD | -15.32% |
| 1999 Q1 | 1.89 Million USD | -8.01% |
| 1998 Q3 | 1.77 Million USD | 35.55% |
| 1998 Q4 | 2.06 Million USD | 16.24% |
| 1998 FY | 2.2 Million USD | 260.14% |
| 1998 Q1 | 400 Thousand USD | -20.0% |
| 1998 Q2 | 1.3 Million USD | 227.0% |
| 1997 Q4 | 500 Thousand USD | 0.0% |
| 1997 FY | 610.87 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Arrayit Corporation | 4.37 Million USD | 79.142% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 96.469% |
| Bioqual, Inc. | 58.59 Million USD | 98.442% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 94.031% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.988% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 85.659% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | 13.179% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 97.73% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -104.023% |
| InVitro International | 792.62 Thousand USD | -15.186% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 91.798% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 87.362% |
| NovelStem International Corp. | 12 Thousand USD | -7508.333% |
| Optigenex Inc. | 465.97 Thousand USD | -95.935% |
| PharmChem, Inc. | 6.01 Million USD | 84.815% |
| Proteome Sciences plc | 6.4 Million USD | 85.736% |
| Response Genetics, Inc | 18.04 Million USD | 94.939% |
| Rennova Health, Inc. | 13.03 Million USD | 92.996% |
| RushNet, Inc. | 1.78 Million USD | 48.934% |
| ScreenPro Security Inc. | 1.91 Million USD | 52.301% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 75.943% |
| Todos Medical Ltd. | 7.69 Million USD | 88.135% |